-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Eli Lilly and Company and Incyte jointly announced positive long-term results from a pivotal Phase 3 clinical trial of the JAK inhibitor baricitinib (Olumiant) in patients with severe alopecia areata
.
About 40% of patients treated with the 4 mg dose of baricitinib had more than 80% scalp hair coverage at 52 weeks of treatment
Alopecia areata is the second most common hair loss symptom in the world, with about 147 million patients worldwide and about 4 million in China
.
It is an autoimmune disease that causes partial or complete loss of hair on the scalp, face, or other parts of the body as the immune system attacks the hair follicles
Baricitinib is an oral JAK inhibitor that has been approved by the FDA for the treatment of rheumatoid arthritis
.
In 2020, it received Breakthrough Therapy designation from the FDA for the treatment of alopecia areata
▲The performance of a previous patient with severe alopecia areata before treatment and after receiving baricitinib for 8 months (Image source: Reference [2])
At baseline, 85.
5% of treated patients had hair loss, and 69.
4% and 57.
9% of patients had significant eyebrow and eyelash loss
.
The average age of the patients was 37.
After 52 weeks of treatment with 4 mg of baricitinib, 39% (n=201/515) of patients had significant hair regrowth, with more than 80% scalp hair coverage
.
Nearly three-quarters of these patients (74.
"Whether all hair is lost, or partial hair loss or loss of eyebrows or eyelashes, this autoimmune disease affects people of all ages and can have serious consequences
," said Dr.
Brett King, professor of dermatology at Yale University School of Medicine.
References:
References:[1] Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies.
[1] Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies.
[2] Olamiju et al.
, (2019).
Treatment of severe alopecia areata with baricitinib.
JAAD case reports, DOI: https://doi.
org/10.
1016/j.
jdcr.
2019.
07.
005
